Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Getting under the skin.
Lavoie JM, Gelmon KA. Lavoie JM, et al. Among authors: gelmon ka. Eur J Cancer. 2017 Sep;82:228-229. doi: 10.1016/j.ejca.2017.04.028. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28592381 No abstract available.
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
Davidson JA, Cromwell I, Ellard SL, Lohrisch C, Gelmon KA, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu DN, Yoshizawa C, Chao C, Peacock S, Chia SK. Davidson JA, et al. Among authors: gelmon ka. Eur J Cancer. 2013 Jul;49(11):2469-75. doi: 10.1016/j.ejca.2013.03.009. Epub 2013 Apr 20. Eur J Cancer. 2013. PMID: 23611660
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators. Gelmon KA, et al. Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1. Eur J Cancer. 2021. PMID: 34087573 Free article. Clinical Trial.
Adjuvant systemic therapy and survival after breast cancer.
Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A. Olivotto IA, et al. Among authors: gelmon ka. N Engl J Med. 1994 Mar 24;330(12):805-10. doi: 10.1056/NEJM199403243301201. N Engl J Med. 1994. PMID: 8114832 Free article.
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Waterhouse DN, et al. Among authors: gelmon ka. Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. doi: 10.2174/156800906778194586. Curr Cancer Drug Targets. 2006. PMID: 17017873 Review.
237 results